June Lee Sells 5,000 Shares of Myokardia Inc (MYOK) Stock
Myokardia Inc (NASDAQ:MYOK) insider June Lee sold 5,000 shares of the company’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $60.81, for a total value of $304,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
June Lee also recently made the following trade(s):
- On Friday, September 21st, June Lee sold 5,000 shares of Myokardia stock. The stock was sold at an average price of $63.13, for a total value of $315,650.00.
Shares of MYOK stock opened at $57.06 on Friday. Myokardia Inc has a fifty-two week low of $35.55 and a fifty-two week high of $67.79.
Hedge funds have recently made changes to their positions in the company. Prudential Financial Inc. acquired a new position in shares of Myokardia in the third quarter valued at about $205,000. Great West Life Assurance Co. Can increased its holdings in shares of Myokardia by 92.7% in the second quarter. Great West Life Assurance Co. Can now owns 3,276 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 1,576 shares during the period. SG Americas Securities LLC acquired a new position in shares of Myokardia in the second quarter valued at about $191,000. GSA Capital Partners LLP acquired a new position in shares of Myokardia in the third quarter valued at about $292,000. Finally, Amalgamated Bank acquired a new position in shares of Myokardia in the second quarter valued at about $231,000. 88.55% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.dailypolitical.com/2018/12/08/june-lee-sells-5000-shares-of-myokardia-inc-myok-stock.html.
MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression.
Featured Story: How can you know how many shares are floating?
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.